Ventripoint Diagnostics Ltd. (VPTDF) 0.0550 $VPTDF
German Heart Group Verifies Accuracy of Ventripoint's VMS(TM) Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging
Marketwire - Mon Jul 07, 10:22AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions.
Ventripoint to Exhibit at the 25th Annual Scientific Sessions of the American Society of Echocardiography
Marketwire - Fri Jun 20, 8:08AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that it will be exhibiting at the 25th Annual Scientific Sessions hosted by the American Society of Echocardiography (ASE) in Portland, Oregon, held June 20th through June 24th.
Ventripoint Extends its Near-Term Secured Debenture
Marketwire - Fri May 30, 6:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation" (TSX VENTURE: VPT) is pleased to announce that it has come to an agreement with its major secured debenture-holder to amend the terms of the USD$748,000 debenture (the "Debenture" so that it is convertible into common shares of the Corporation ("Common Shares" at a price of USD$.0748 per Common Share. In addition, the maturity date of the Debenture has changed from July 18, 2014 to February 27, 2015. All other material terms of the Debenture remain the same. It is the intention of the debenture-holder to convert the debt into shares, which will be subject to a 4-month hold period. The Company will pay a one-time fee of USD$25,000 to the Debenture holder to affect these amendments to the Debenture. The TSX Venture Exchange has conditionally approved the amendment of the Debenture.
IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH).
IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency" a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.
Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements.
University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
Marketwire - Thu Jul 25, 6:01AM CDT
Ventripoint Diagnostics (TSX VENTURE: VPT)(OTCQX: VPTDF) is pleased to announce that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled "Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction(i) in Pulmonary Arterial Hypertension" in the Journal of the American Society of Echocardiography, Volume 26, Issue 8, Pages 860-867, August 2013.
VentriPoint Announces Closing of Private Placement and Corporate Update
Marketwire - Mon Jun 24, 6:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT)(OTCQX: VPTDF) announces that it has completed a first closing of the second of its two previously announced non-brokered private placements and is providing a corporate update.
German Heart Group Verifies Accuracy of Ventripoint's VMS(TM) Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging
Marketwire - Mon Jul 07, 10:22AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions. Ventripoint to Exhibit at the 25th Annual Scientific Sessions of the American Society of Echocardiography
Marketwire - Fri Jun 20, 8:08AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that it will be exhibiting at the 25th Annual Scientific Sessions hosted by the American Society of Echocardiography (ASE) in Portland, Oregon, held June 20th through June 24th. Ventripoint Extends its Near-Term Secured Debenture
Marketwire - Fri May 30, 6:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"
(TSX VENTURE: VPT) is pleased to announce that it has come to an agreement with its major secured debenture-holder to amend the terms of the USD$748,000 debenture (the "Debenture" so that it is convertible into common shares of the Corporation ("Common Shares" at a price of USD$.0748 per Common Share. In addition, the maturity date of the Debenture has changed from July 18, 2014 to February 27, 2015. All other material terms of the Debenture remain the same. It is the intention of the debenture-holder to convert the debt into shares, which will be subject to a 4-month hold period. The Company will pay a one-time fee of USD$25,000 to the Debenture holder to affect these amendments to the Debenture. The TSX Venture Exchange has conditionally approved the amendment of the Debenture. IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Mon Mar 10, 8:35AM CDT
Trading resumes in:
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
Marketwire - Mon Mar 10, 7:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH). IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Mar 07, 2:55PM CST
The following issues have been halted by IIROC:
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Ventripoint Announces 510(k) Submission for VMS Heart Analysis System and Issuance of Shares for Debt
Marketwire - Thu Jan 23, 6:01AM CST
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) is pleased to announce that it has submitted to the US Federal Drug Administration ("the Agency"
a new 510(k) for clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH). Yieldex Wraps Up 2013 With 1.5 Trillion Impressions
Marketwire - Thu Dec 19, 8:30AM CST
Yieldex, the leading provider of inventory and revenue management solutions for digital publishers, today announced that 1.5 trillion ad impressions have been analyzed via the YieldEdge platform this year, demonstrating that companies are increasing their investment and reliance on big data analytics to grow their businesses.
Ventripoint Announces Regulatory Update for VMS(tm) Heart Analysis System
ACCESSWIRE - Fri Dec 13, 4:29PM CST
Seattle, Washington, December 13, 2013 - Ventripoint Diagnostics Ltd. (TSXV:VPT) (the Company or Ventripoint) is pleased to announce that the it has responded within the specified 30-day period to the non-substantially equivalent (NSE) letter received from the U.S. FDA on November 14, 2013, and has had numerous discussions with the FDA to identify the best and quickest pathway to obtain clearance for the VMS(TM) heart analysis system for use in Pulmonary Arterial Hypertension (PAH).
Ventripoint Announces Closing of Private Placement
Marketwire - Mon Jul 29, 5:49PM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the second closing of the second of its two previously announced non-brokered private placements. University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
Marketwire - Thu Jul 25, 6:01AM CDT
Ventripoint Diagnostics (TSX VENTURE: VPT)(OTCQX: VPTDF) is pleased to announce that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled "Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction(i) in Pulmonary Arterial Hypertension" in the Journal of the American Society of Echocardiography, Volume 26, Issue 8, Pages 860-867, August 2013.
VentriPoint Announces Closing of Private Placement and Corporate Update
Marketwire - Mon Jun 24, 6:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT)(OTCQX: VPTDF) announces that it has completed a first closing of the second of its two previously announced non-brokered private placements and is providing a corporate update. 
